Korea Exchange’s decision on Kyungnam Pharm to make subject to Substantive Examination for Listing Eligibility
The Exchange Korea reviewed possibilities to delist Kyungnam Pharm based on general qualifications in accordance with Article 38 of 2 Item of Number 2 of the KOSDAQ Rules, and officially announced that the company is subject to the Substantive Examination for Listing Eligibility on the 22nd.
Und...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
